- Trials with a EudraCT protocol (74)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
74 result(s) found for: Neoplasms AND Mantle Cell Lymphoma.
Displaying page 2 of 4.
| EudraCT Number: 2015-005008-27 | Sponsor Protocol Number: KTE-C19-102 | Start Date*: 2018-08-16 | ||||||||||||||||
| Sponsor Name:Kite Pharma, Inc. | ||||||||||||||||||
| Full Title: A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2) | ||||||||||||||||||
| Medical condition: Relapsed/Refractory Mantle Cell Lymphoma (MCL) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2016-002972-29 | Sponsor Protocol Number: CART19-BE-01 | Start Date*: 2017-05-16 | ||||||||||||||||||||||||||
| Sponsor Name:IDIBAPS | ||||||||||||||||||||||||||||
| Full Title: Pilot study on the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (... | ||||||||||||||||||||||||||||
| Medical condition: Patients with leukemia or lymphoma refractory to therapy | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2014-001911-38 | Sponsor Protocol Number: GELTAMOMAN2 | Start Date*: 2014-09-19 | |||||||||||
| Sponsor Name:Grupo Español de Linfoma y Trasplante Autólogo de Médula ósea | |||||||||||||
| Full Title: AN OPEN MULTICENTER PHASE II STUDY OF EFFICACY AND TOXICITY OF MAINTENANCE SUBCUTANEOUS RITUXIMAB AFTER RESCUE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA NON-ELIGIBLE FO... | |||||||||||||
| Medical condition: PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA NON-ELIGIBLE FOR AUTO OR ALLO STEM CELL TRANSPLANTATION | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-007246-60 | Sponsor Protocol Number: NLG-MCL4(LENA-BERIT) | Start Date*: 2009-06-23 | |||||||||||||||||||||
| Sponsor Name:Nordic Lymphoma Group | |||||||||||||||||||||||
| Full Title: Lenalidomide, bendamustine and rituximab as first-line therapy for patients >65 years with mantle cell lymphoma | |||||||||||||||||||||||
| Medical condition: Mantle cell lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: SE (Completed) FI (Completed) DK (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2009-017675-16 | Sponsor Protocol Number: OFT113725 | Start Date*: 2010-11-30 | ||||||||||||||||
| Sponsor Name:Plymouth Hospitals NHS Trust | ||||||||||||||||||
| Full Title: Phase II Trial of Single Agent Ofatumumab in Relapsed / Refractory Mantle Cell Lymphoma | ||||||||||||||||||
| Medical condition: Relapsed or refractory Mantle Cell Lymphoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2018-001850-80 | Sponsor Protocol Number: NLG-MCL8 | Start Date*: 2021-04-07 |
| Sponsor Name:Skåne University Hospital | ||
| Full Title: Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma | ||
| Medical condition: Mantle Cell Lymphoma (MCL) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-000870-27 | Sponsor Protocol Number: D361FC00001 | Start Date*: 2021-08-02 | |||||||||||||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||||||||||||
| Full Title: A Modular Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL) | |||||||||||||||||||||||
| Medical condition: Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: FR (Completed) ES (Trial now transitioned) DK (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2007-005472-13 | Sponsor Protocol Number: Ply-5013 | Start Date*: 2008-09-19 | |||||||||||
| Sponsor Name:Plymouth Hospitals NHS Trust | |||||||||||||
| Full Title: Phase II Single Agent Lenalidomide (Revlimid) in Relapsed / Refratory Mantle Cell Lymphoma. | |||||||||||||
| Medical condition: Relapsed / Refractory Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-003740-13 | Sponsor Protocol Number: RC14_0048 | Start Date*: 2015-09-11 | |||||||||||
| Sponsor Name:CHU de Nantes | |||||||||||||
| Full Title: A phase I/II trial of Obinutuzumab, ABT-199 (GDC-0199) plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma patients -OAsIs | |||||||||||||
| Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-022939-11 | Sponsor Protocol Number: PCYC-1104-CA | Start Date*: 2011-05-17 | ||||||||||||||||
| Sponsor Name:Pharmacyclics, Incorporated | ||||||||||||||||||
| Full Title: Multicenter phase 2 study of Bruton’s tyrosine kinase (Btk) inhibitor, PCI-32765, in relapsed or refractory mantle cell lymphoma | ||||||||||||||||||
| Medical condition: Relapsed or refractory mantle cell lymphoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Completed) DE (Completed) AT (Completed) | ||||||||||||||||||
| Trial results: Removed from public view | ||||||||||||||||||
| EudraCT Number: 2012-000601-74 | Sponsor Protocol Number: PCI-32765MCL3001 | Start Date*: 2014-01-24 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV | |||||||||||||
| Full Title: A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects with Relapsed or Refractory Mantle Cell L... | |||||||||||||
| Medical condition: Relapsed or refractory Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) BE (Completed) DE (Completed) GB (Completed) IE (Completed) HU (Completed) PT (Completed) CZ (Completed) NL (Completed) ES (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-002208-41 | Sponsor Protocol Number: CBKM120Z2402 | Start Date*: 2013-03-07 | ||||||||||||||||
| Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
| Full Title: An open-label phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma | ||||||||||||||||||
| Medical condition: | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) IT (Completed) ES (Completed) BE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2010-020820-23 | Sponsor Protocol Number: MI-CP218 | Start Date*: 2011-03-30 | ||||||||||||||||||||||||||
| Sponsor Name:MedImmune | ||||||||||||||||||||||||||||
| Full Title: A Phase 1/2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | ||||||||||||||||||||||||||||
| Medical condition: Indolent (follicular lymphoma [FL]) and aggressive (diffuse large B-cell lymphoma [DLBCL], mantle cell lymphoma [MCL], or CLL) B-cell malignancies. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2020-000354-10 | Sponsor Protocol Number: CC-220-NHL-001 | Start Date*: 2020-11-23 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Celgene Corporation | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY TO ASSESS SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF CC-220, ALONE AND IN COMBINATION WITH AN ANTI-CD20 MONOCLONAL ANTIBODY (MAB) IN SUBJECTS W... | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Relapsed or refractory lymphoma including the following subtypes: Aggressive B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma and class... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2007-005669-37 | Sponsor Protocol Number: 26866138-LYM-3002;Phase3 | Start Date*: 2008-04-29 | |||||||||||
| Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
| Full Title: A Randomised, Open-Label, Multicentre Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, ... | |||||||||||||
| Medical condition: Patients with newly diagnosed Mantle Cell Lymphoma who are not eligible for bone marrow transplant. To determine which regimen of chemotherapy (VcR-CAP or R-CHOP) provides greater benefit in new... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) PT (Completed) CZ (Completed) AT (Completed) IT (Completed) HU (Completed) DE (Completed) ES (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-000820-20 | Sponsor Protocol Number: NVG111-101 | Start Date*: 2020-10-30 | ||||||||||||||||
| Sponsor Name:NovalGen Ltd | ||||||||||||||||||
| Full Title: AN OPEN-LABEL, PHASE 1/2, FIRST IN HUMAN STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF NVG-111 IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA ... | ||||||||||||||||||
| Medical condition: RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA AND MANTLE CELL LYMPHOMA | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2020-005297-10 | Sponsor Protocol Number: DCL-16-001 | Start Date*: 2021-05-19 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Cellectar Biosciences, Inc. | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobu... | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Part A: MM (multiple myeloma), CLL/SLL(chronic lymphocytic leukemia/small lymphocytic lymphoma), LPL/WM(lymphoplasmacytic lymphoma/ Waldenstrom's Macroglobulinemia), MZL(marginal zone lymphoma), MC... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: CZ (Completed) GR (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) FI (Completed) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-006556-14 | Sponsor Protocol Number: RHCART1A | Start Date*: 2022-07-08 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Rigshospitalet | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: CLIC-1901 CAR T-cells for treatment of patients with relapsed/refractory CD19-positive ALL and NHL (DAN-CART 1901) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Acute Lymphoblastic Leukemia and B-cell Non Hodgkin Lymphoma | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DK (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2016-003579-22 | Sponsor Protocol Number: MO39107 | Start Date*: 2017-08-02 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Roche Farma S.A. (Soc.unipersonal)que realiza el ensayo en España y que actúa como representante de F.Hoffmann- La Roche | ||||||||||||||||||||||||||||||||||||||
| Full Title: A PHASE II STUDY EXPLORING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB ADMINISTERED IN COMBINATION WITH OBINUTUZUMAB OR RITUXIMAB ANTI-CD20 THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMP... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Relapsed/Refractory Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) and Waldenström Macroglobulinemia (WM) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Completed) DE (Completed) LV (Completed) GR (Completed) SK (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2006-006090-24 | Sponsor Protocol Number: Ply26s | Start Date*: 2007-02-23 | |||||||||||
| Sponsor Name:Plymouth Hospitals NHS Trust | |||||||||||||
| Full Title: A Parallel Randomised Phase II Trial of CHOP Chemotherapy With or Without Bortezomib in Relapsed Mantle Cell Lymphoma | |||||||||||||
| Medical condition: Relapsed, or refractory mantle cell lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
